Articles tagged with: Clinical Trial
Headline, News »
Onyx Pharmaceuticals announced yesterday the results of an ongoing Phase 2b trial of single-agent carfilzomib for heavily pre-treated relapsed and refractory multiple myeloma patients. The overall response rate after 12 cycles of single-agent carfilzomib treatment in this trial was 24 percent, and the median duration of response was 7.4 months.
According to Dr. Michael Kauffman, Chief Medical Officer of Onyx Pharmaceuticals, the company’s newly released results demonstrate the potential for carfilzomib to significantly improve the outlook for relapsed and refractory multiple myeloma patients.
He cited a recent study…
Headline, News, Resources »
This article describes a myeloma patient’s experience participating in a clinical trial. It is part of a series of articles intended to help clarify the clinical trial process.
In August 2008, Phil Brabbs was diagnosed with smoldering myeloma, which most physicians do not treat until symptoms begin and the disease progresses to multiple myeloma. After more than a year of physicians carefully reviewing his blood work, Phil’s smoldering myeloma progressed to multiple myeloma, and his physicians wanted to begin treatment.
Phil’s doctor suggested that he participate in a clinical trial…
Headline, News, Resources »
This article describes a myeloma patient’s experience participating in a clinical trial. It is part of a series of articles intended to help clarify the clinical trial process.
Don was diagnosed with multiple myeloma in 2004. At the age of 69 and despite living with a cancer that attacks his bones, Don inspires fellow myeloma patients by running in marathons. He has completed three marathons so far this year, is running in one tomorrow, and plans on participating in three to four more marathons just this year. Additionally, Don maintains…
Headline, News »
The 46th annual meeting of the American Society of Clinical Oncology (ASCO) kicks off on June 4 in Chicago.
More than 30,000 clinical specialists from all over the world are expected to attend the five day meeting to discuss the most current research in cancer treatment and care. This year’s meeting, which will feature more than 4,000 presentations and posters, will primarily focus on the theme of “Advancing Quality through Innovation.”
The ASCO meeting will include many presentations and seminars focused on multiple myeloma. The ASCO website currently lists over…
Headline, News, Resources »
This guide, which will be published as a series of articles over the next couple of weeks, is intended to help clarify the clinical trial process and to answer common questions so that you can decide whether a clinical trial is the right option for you. The guide will explain the different types of clinical trials, address common concerns, provide answers from physicians to common questions, describe patients’ clinical trial experiences, and provide resources for finding a clinical trial.
If you have decided to participate in a clinical trial, then…
Headline, News, Resources »
This guide, which will be published as a series of articles over the next couple of weeks, is intended to help clarify the clinical trial process and to answer common questions so that you can decide whether a clinical trial is the right option for you. The guide will explain the different types of clinical trials, address common concerns, provide answers from physicians to common questions, describe patients’ clinical trial experiences, and provide resources for finding a clinical trial.
There are many issues that patients worry about when considering whether…
Headline, News, Resources »
This guide, which will be published as a series of articles over the next couple of weeks, is intended to help clarify the clinical trial process and to answer common questions so that you can decide whether a clinical trial is the right option for you. The guide will explain the different types of clinical trials, address common concerns, provide answers from physicians to common questions, describe patients’ clinical trial experiences, and provide resources for finding a clinical trial.
If you are considering participating in a clinical trial, it is…
Featured, Headline, News, Resources »
For many patients with multiple myeloma, common treatment regimens are not always effective against their cancer. In such situations, physicians may recommend turning to new combinations of treatments or newly developing treatments through participation in clinical trials.
Taking part in a clinical trial is a huge decision for both patients and their families, and it is one that should be made with careful consideration.
This guide, which will be published as a series of articles over the next couple of weeks, is intended to help clarify the clinical trial process…
News »
Fred Hutchinson Cancer Center To Field Questions At The Beacon’s Forums This Week – Dr. William Bensinger, myeloma expert at the Fred Hutchinson Cancer Center in Seattle, WA, will be be responding to medical questions posted in the Myeloma Beacon’s forums this week. Readers who have not yet visited the Beacon’s new myeloma discussion forums are encouraged to do so, as they already contain a number of informative postings about topics such as myeloma treatment options, managing treatment side effects, and alternative myeloma therapies.
Treanda Combination Therapy Enters Phase 1B/2 Trial For Multiple Myeloma – Last week, the Multiple Myeloma Research Consortium (MMRC) announced the start of a Phase 1B/2 clinical trial that will evaluate a combination of Treanda (bendamustine), Revlimid (lenalidomide) and dexamethasone (Decadron) in relapsed multiple myeloma patients. Treanda is already approved in Germany in combination with prednisone for the treatment of multiple myeloma. In the United States, the drug is approved for the treatment of chronic lymphocytic leukemia and certain lymphomas. For more information, see the MMRC press release or the clinical trial description.
MMRF Kicks Off Race For Research 5K Walk/Run Series – On April 25, the Multiple Myeloma Research Foundation (MMRF) will kick off its annual Race For Research 5K Walk/Run series to raise awareness and funds for multiple myeloma research. The events will take place in eight cities across the Unites States. The first one is scheduled for April 25 in San Francisco. For more information and registration details, see the MMRF Web site.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
Featured, Headline, News, Resources »
Curcumin has been garnering increased attention as a potential anticancer treatment. It is the major active compound in turmeric, a popular Indian spice made from the rhizomes, or underground stalks, of a plant in the ginger family.
In multiple myeloma and the precursor condition monoclonal gammopathy of undetermined significance (MGUS), cell culture studies and one animal study have shown that curcumin can kill cancer cells and prevent them from multiplying. The Beacon also found two early-stage clinical trials studying curcumin’s effects in people with multiple myeloma and MGUS. Their results…